Publications

Featured Publications

Interleukin-18 Engineered For Resistance to IL-18 Binding Protein (IL-18BP) and Half-Life Extension to Enhance Its Therapeutic Potential

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2024


>> View Poster

Generation of tumor targeted self-assembling split IL-12p35 and IL-12p40 subunits for the treatment of cancer

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2024


>> View Poster

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2022


>> View Presentation

All Publications

  • Filter by Indications

  • Filter by Clinical Study

Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1

Melanoma Bridge

calendar icon December 2021


>> View Presentation

Nemvaleukin Alfa, a Novel Engineered IL-2 Cytokine, in Combination With the Anti-PD-1 Antibody Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ION-01 Study)

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2021


>> View Poster

ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma

Society for Melanoma Research Congress

calendar icon October 2021


>> View Poster

Clinical Development of Nemvaleukin Alfa (ALKS 4230) for Advanced Solid Tumors With High Unmet Need: From Design to Bench to Bedside

Cytokines in Cancer Immunotherapy Workshop

calendar icon October 2021


>> View Poster

Antitumor Efficacy and Immune Profiling of the Mouse Ortholog of Nemvaleukin Alfa, a Novel Engineered IL-2 Fusion Protein, in an Orthotopic Mouse Model of Small Cell Lung Cancer Alone or in Combination with Standard Chemotherapy

European Society for Medical Oncology (ESMO) Congress

calendar icon September 2021


>> View Poster

ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma

European Society for Medical Oncology (ESMO) Congress

calendar icon September 2021


>> View Poster

Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys

The Journal of Pharmacology and Experimental Therapeutics

calendar icon August 2021


>> View Article

A Phase 2 Clinical Trial of Nemvaleukin Alfa (ALKS 4230) Combined With Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): the ION-01 Trial

American Head & Neck Society (AHNS) International Conference

calendar icon July 2021


>> View Poster

Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1

European Association of Dermato Oncology (EADO) Congress

calendar icon April 2021


>> View Poster

Phase 1/2 Study of Subcutaneously Administered ALKS 4230, a Novel Engineered Cytokine, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors: ARTISTRY-2

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2020


>> View Poster

ALKS 4230: A Novel, Engineered Interleukin Variant Immunotherapy – Clinical Data Updates from ARTISTRY-1 Trial

European Society for Medical Oncology Virtual Congress 2020

calendar icon September 2020


>> View Presentation

The Combination of a Mouse Ortholog of ALKS 4230, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, and the Angiogenesis Inhibitor Lucitanib Enhances Antitumor Activity

American Association for Cancer Research Annual Meeting

calendar icon April 2020


>> View Poster